Antimicrobial and Anticancer Peptides

Antimicrobial and Anticancer Peptides

  • Neil M. O’Brien-Simpson
  • Ralf Hoffmann
  • C.S. Brian Chia
  • John D. Wade
Publisher:Frontiers Media SAISBN 13: 9782889454709ISBN 10: 2889454703

Paperback & Hardcover deals ―

Amazon IndiaGOFlipkart GOSnapdealGOSapnaOnlineGOJain Book AgencyGOBooks Wagon₹8,395Book ChorGOCrosswordGODC BooksGO

e-book & Audiobook deals ―

Amazon India GOGoogle Play Books GOAudible GO

* Price may vary from time to time.

* GO = We're not able to fetch the price (please check manually visiting the website).

Know about the book -

Antimicrobial and Anticancer Peptides is written by Neil M. O’Brien-Simpson and published by Frontiers Media SA. It's available with International Standard Book Number or ISBN identification 2889454703 (ISBN 10) and 9782889454709 (ISBN 13).

In 2014, the World Health Organization (WHO) listed cancer as the second leading cause of death and highlighted antimicrobial resistance as “a key global health challenge” that may, in a worst case scenario, lead to an annual death toll of 10 million by 2050, which would exceed predicted cancer deaths by 20%. Novel promising therapeutic options to reduce morbidity and mortality of both infectious microbial diseases and cancer are being developed based on antimicrobial peptides (AMPs), i.e., evolutionary proven antibiotics that also possess anti-cancer activities. Intriguingly, AMPs and anti-cancer peptides (ACPs) rely typically on novel mechanisms and cellular targets not used by current antibiotics or chemotherapeutics. Initiated by presentations at the International Meeting of Antimicrobial Peptides in 2016 (IMAP 2016), hosted at Leipzig University, Germany, this book compiles the most recent strategies and promising lead compounds for treating multi- and pan-resistant microbes and chemo-resistant cancer cells in fourteen different chapters representing leading research groups from five different continents. In this respect, the book shall stimulate new avenues of thinking and strategies in tackling forthcoming antimicrobial and cancer resistance health threats with the hope that the scenarios recently reported by the WHO will never eventuate.